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“The boy believes he will be a proper I, a proper fellow, only when he has become a man; the 
man thinks, only in the other world will he be something proper” 
Max Stirner, The Ego and its Own 
  
ABSTRACT 
 
Alzheimer’s disease (AD) is the most common form of dementia in the elderly characterized 
by difficulties in memory, disturbances in language, changes in behavior, and impairments in 
daily life activities. By the time cognitive impairment manifests, substantial synaptic and 
neuronal degeneration has already occurred. Therefore, patients need to be diagnosed as early 
as possible at a preclinical or presymptomatic stage. This will be important when disease-
modifying treatments exist in the future.  
The main focus of this thesis is on the study of structural neuroimaging in AD and in 
prodromal stages of the disease. We emphasize the use of statistical learning for the analysis 
of structural neuroimaging data to achieve individual prediction of disease status and 
conversion from prodromal stages. The main aims of the thesis were to develop and validate 
computerized tools to identify patterns of atrophy with the potential of becoming markers of 
AD pathology using structural magnetic resonance imaging (sMRI) data and to develop a 
segmentation tool for Computed Tomography (CT). 
Using automated neuroanatomical software we measured multiple brain structures that were 
given to statistical learning techniques to create discriminative models for prediction of 
presence of disease and conversion from prodromal stages. Building statistical models based 
on sMRI data we investigated optimal normalization strategies for the combination of 
structural measures such as cortical thickness, cortical and subcortical volumes (Study I). A 
baseline model was created based on the optimal normalization strategy and combination of 
structural measures. This model was used to compare the discrimination ability of different 
statistical learning algorithms (decision trees, artificial neural networks, support vector 
machines and orthogonal partial least squares (OPLS)). Additionally, the addition of age, 
years of education and APOE phenotype was added to the baseline model to assess the 
impact on discrimination ability (Study II). The OPLS classification algorithm was trained 
on the baseline model to produce a structural index reflecting information about AD-like 
patterns of atrophy from each individual’s sMRI data. Additional longitudinal information at 
one-year follow-up was used to characterize the temporal evolution of the derived index 
(Study III). Since total intracranial volume (ICV) remains a morphological measure of 
interest and CT is today widely used in routine clinical investigations, we developed and 
validated an automated segmentation algorithm to estimate ICV from CT scans (Study IV). 
We believe computerized tools (automated neuroimaging software and statistical 
discriminative algorithms) have significantly enriched our knowledge and understanding of 
associated neurodegenerative pathology, its effects on cognition and interaction with age. 
These tools were mainly developed for research purposes but we believe all accumulated 
knowledge and insights could be translated into clinical settings, however, that is a challenge 
that remains open for future studies.  
LIST OF SCIENTIFIC PAPERS 
 
I. Westman, E., Aguilar, C., et al., 2013. Regional magnetic resonance imaging 
measures for multivariate analysis in Alzheimer's disease and mild cognitive 
impairment. Brain Topography, Volume 26, Issue 1, p. 9-23. 
 
II. Aguilar, C., Westman, E., et al., 2013. Different multivariate techniques for 
automated classification of MRI data in Alzheimer’s disease and mild 
cognitive impairment. Psychiatry Research: Neuroimaging, Volume 212, 
Issue 2, p. 89-98. 
 
III. Aguilar, C., Muehlboeck, S., et al., 2014. Application of a MRI based index 
to longitudinal atrophy change in Alzheimer disease, mild cognitive 
impairment and healthy older individuals in the AddNeuroMed cohort. 
Frontiers in Aging Neuroscience. doi: 10.3389/fnagi.2014.00145. 
 
IV. Aguilar, C., Edholm, K., et al. 2015. Automated CT-based segmentation and 
quantification of total intracranial volume. European Ragiology, doi:  
10.1007/s00330-015-3747-7 (epub ahead of print). 
  
 Publications not included in thesis 
 Pereira JB, Cavallin L, Spulber G, Aguilar C, et al., 2013. Influence of age, 
disease onset and ApoE4 on visual medial temporal lobe atrophy cut-offs. 
Journal of Internal Medicine. Volume 275, Issue 3, p. 317-330. 
 Lebedev AV, Westman E, Beyer MK, Kramberger MG, Aguilar C, et al., 
2013. Multivariate classification of patients with Alzheimer's and dementia 
with Lewy bodies using high-dimensional cortical thickness measurements: 
an MRI surface-based morphometric study. Journal of Neurology. Volume 
260, Issue 4, p. 1104-1015. 
 
 
Paper I © 2012, The Author(s). Open-access article distributed under the terms of 
the Creative Commons Attribution License. 
Paper II © 2012. Reprinted with permission from Elsevier. 
Paper III © 2014, The Authors. Open-access article distributed under the terms of 
the Creative Commons Attribution License. 
Paper IV © 2015. Reprinted with permission from Springer. 
 
  
CONTENTS 
1 Aging and Alzheimer’s disease ...................................................................................... 7 
1.1 Neuropathology of Alzheimer’s disease ............................................................... 7 
1.2 Modulators of phenotypic expression ................................................................... 9 
1.2.1 Aging and neuropathology ...................................................................... 10 
1.2.2 APOE and AD pathogenesis ................................................................... 10 
1.2.3 Education and brain reserve .................................................................... 10 
1.3 Mild cognitive impairment .................................................................................. 11 
1.4 Evaluation of cognitive function ......................................................................... 11 
2 Imaging Alzheimer’s disease ........................................................................................ 13 
2.1 Computed Tomography and Magnetic Resonance Imaging .............................. 13 
2.2 Automated neuroimaging pipelines .................................................................... 14 
2.3 Individual classification based on statistical learning ........................................ 15 
3 Statistical learning ......................................................................................................... 17 
3.1 Estimation of a functional relationship ............................................................... 17 
3.2 Linear regression ................................................................................................. 18 
3.3 Principal component analysis .............................................................................. 19 
3.4 Partial least squares ............................................................................................. 20 
3.5 Orthogonal PLS ................................................................................................... 20 
3.6 Linear classification ............................................................................................. 20 
3.7 Maximum-likelihood estimation ......................................................................... 21 
3.8 Clustering ............................................................................................................. 22 
4 Aims of the thesis .......................................................................................................... 23 
5 Methodology.................................................................................................................. 24 
5.1 Ethical considerations .......................................................................................... 24 
5.2 Studies I-III .......................................................................................................... 24 
5.3 Study IV ............................................................................................................... 27 
5.4 Preliminary studies .............................................................................................. 29 
6 Results ............................................................................................................................ 32 
7 Discussion ...................................................................................................................... 37 
8 Conclusions and future perspectives............................................................................. 42 
9 Acknowledgements ....................................................................................................... 43 
10 References ..................................................................................................................... 45 
 
  
LIST OF ABBREVIATIONS 
Aβ Amyloid-beta 
AD Alzheimer’s disease 
ADAS-cog Alzheimer’s Disease Assessment Scale - cognition 
ADNI Alzheimer’s Disease Neuroimaging Initiative 
ADRDA Alzheimer’s Disease and Related Disorders Association 
ANN Artificial neural networks 
ANOVA Analysis of variance 
APOE Apolipoprotein E 
APP Amyloid precursor protein 
BACE 1 Beta-site APP cleaving enzyme 1 
BET Brain extraction tool 
CDR Cognitive Dementia Rating 
CSF Cerebrospinal fluid 
CT Computed Tomography 
DICOM Digital Imaging and Communications in Medicine 
DSM Diagnostic Statistical Manual 
EM Expectation maximization 
𝑓(𝑋) Unknown function of 𝑋 = 𝑋1, 𝑋2, 𝑋3, … 
FDG Fluordeoxyglucouse 
GDS Geriatric depression scale 
GM Gray matter 
HU Hounsfield unit 
ICV Intracranial volume 
InnoMed Innovative Medicines 
𝐿(𝑌, 𝑓(𝑋)) Loss function 
MCI Mild cognitive impairment 
MCI-c MCI converter 
MLE Maximum-likelihood estimation 
MLME Maximum-likelihood mixture estimation 
mm Millimeters 
  
mm
3
 Cubic millimeters 
MMSE Mini mental state examination 
MPRAGE Magnetization Prepared Rapid Acquisition with Gradient 
Echo 
MR Magnetic resonance 
MRI Magnetic resonance imaging 
mSV Millisievert 
NINCDS National Institute of Neurological and Communicative 
Disorders and Stroke 
OPLS Orthogonal PLS 
PCA Principal component analysis 
PET Positron emission tomography 
PLS Partial least squares 
P-tau Phosphorylated tau 
𝑅[𝑓] Expected risk 
𝑅𝑔𝑢𝑎[𝑓] Guaranteed risk 
RSS Residual sum-of-squares 
sMRI Structural MRI 
SPECT Single-photon emission computed tomography 
SPM Statistical parametric maps 
SVM Support vector machines 
TICV Total ICV 
Trees Decision trees 
T1-w T1-weighted 
VC Vapnik-Chervonenkis 
WM White matter 
WMCs White-matter changes 
 
  7 
1 AGING AND ALZHEIMER’S DISEASE 
Global increased life expectancy has implied a rising elderly population and created new 
challenges associated with a greater frequency of brain disorders due to aging, particularly of 
dementia cases [1], [2]. Consequences from suffering biological and cognitive degeneration 
include frailty, weakness, shortened life expectancy and loss of independence. Dementia can 
be defined as an acquired syndrome producing brain dysfunction (cognitive impairment, 
deterioration of intellect and personality changes) as part of aging due to cell death caused by 
brain disease [3]. The most common cause of dementia is Alzheimer’s disease (AD), 
followed by vascular dementia, Lewy body dementia, frontotemporal dementia and 
Parkinson’s disease. 
1.1 NEUROPATHOLOGY OF ALZHEIMER’S DISEASE 
The concept of AD as a unique entity originated from observations of severe dementia in the 
elderly accompanied by histomorphological changes: neuritic plaques, neurofibrillary tangles 
and granulovacuolar degeneration [4]. Like other neurodegenerative diseases, AD is 
fundamentally a disorder of altered protein folding and aggregation [5], specifically amyloid 
beta (Aβ) and tau proteins [6]. Misfolded proteins aggregate together leading to a buildup of 
cellular gunk that causes damage inside or outside cells, eventually consuming entire brain 
regions [7].  Discovery and characterization of amyloid fibril (neuritic) plaques and 
cerebrovascular angiopathy in post-mortem brain studies of diseased patients prompted the 
development of an Aβ peptide cascade hypothesis for the study of the pathogenesis of AD 
[8]–[10].  
Aβ is a 38-43 amino acid-long peptide that is cleaved out from the transmembrane protein 
amyloid precursor protein (APP) by sequential endoproteolysis by beta-site APP cleaving 
enzyme 1 (BACE 1)/β-secretase and presenilin/γ-secretase complexes. APP can also undergo 
non-amyloidogenic proteolysis by α-secretase. Aβ monomers undergo a dramatic 
conformational change to form a beta sheet-rich tertiary structure that aggregates to form 
amyloid fibrils. These fibrils deposit outside neuronal cells in dense formations known as 
senile or neuritic plaques, in less dense aggregates known as diffuse plaques, and in the walls 
of small blood vessels in a process called amyloid angiopathy. Tau protein is a microtubule-
associated protein expressed in neurons. Tau protein stabilizes microtubules in the cell 
cytoskeleton and is normally regulated by phosphorylation. Abnormal hyperphosphorylation 
of tau protein (P-tau) in AD results in the loss of tau function causing inhibition and 
disruption of microtubules [11]. In addition, changes in conformation transform the unfolded 
monomer to a structured polymer, causing neurofibrillary tangle formation and synapse loss 
[12], [13]. 
The degenerating aging process involves the accumulation of structural damage and a 
deficient metabolic balance mechanism. Aging renders the brain vulnerable to Aβ 
neurotoxicity which starts to accumulate in the absence of neuritic pathology as part of 
normal aging [14]. Likewise, accumulation of neurofibrillary tangles in medial temporal lobe 
structures, like the entorhinal cortex, occurs as part of normal aging and is not specific for AD 
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[15]. While elderly individuals show AD-like changes, such as neuritic tau pathology in 
neocortical regions, some maintain their mental performance [16]–[18]. This generated the 
idea of an asymptomatic prodromal stage characterized by increased Aβ accumulation in the 
brain. Accumulated evidence from research suggests the pathology underlying AD begins to 
develop 10-20 years prior to cognitive impairment [19]–[21]. Since pathology precedes 
cognitive impairment, it follows that the onset of initial symptoms (dysfunction of episodic 
memory) may develop when a threshold level of neuronal and synaptic loss is reached, 
starting in the entorhinal cortex and hippocampus, in parallel with neurofibrillary tangle 
formation and gliosis. 
The recognition of an irreversible and rapid progressive loss of cognitive abilities in patients 
suffering dementia, as opposed to normal age-related decline, together with the idea of a 
major loss of brain tissue [22], [23], elicited a systematic study and characterization of the 
stages leading to dementia and premature death. The usually precise pathway of tau 
pathology follows a predictable topographic pattern from the entorhinal cortex via the 
hippocampus to neocortical association areas and, to subcortical nuclei [24], [25]. In contrast, 
Aβ deposition is more diffuse and less predictable, usually beginning in the neocortex and 
later progressing to allocortical regions expanding anterogradely into regions that receive 
neuronal projections from already affected brain areas. At autopsy, all clinically defined AD 
cases display huge amounts of amyloid deposits and widespread tau pathology, as well as, 
massive white matter breakdown due to disconnection of widely distributed neuronal 
networks [26]. 
The degenerative gross structural changes and the assessment of distribution and progression 
patterns of amyloid deposition and neurofibrillary tangles resulted in a chronological 
description of the temporal evolution of atrophy that characterizes patients suffering from AD 
[27]. Culminating in the establishment of a time sequence relationship in the cascade of 
events: brain diseases (such as AD) cause gradual neuronal loss, which causes progressive 
brain dysfunction, which results in progressive cognitive impairment, which culminates in 
dementia. It can be thought of as a sequence of pathophysiological stages: preclinical 
(asymptomatic and with biomarker evidence suggestive of pathology), prodromal (subtle 
cognitive decline and/or subjective memory report) and dementia [28]. 
Structural neuroimaging using Computed Tomography (CT) or Magnetic Resonance Imaging 
(MRI) allows visualization of tissue atrophy which tightly follows the distribution of 
neurofibrillary staging of AD (Figure 1): initial transentorhinal stage affecting the 
transentorhinal and entorhinal cortices, limbic stage spreading to the hippocampus and 
amygdala, and isocortical stage affecting the neocortical association areas of the brain [29]. 
The clinical approach is based on core comprehensive neurological examinations and clinical 
interviews (neuropsychological examinations). But recent research diagnostic criteria has 
shifted from purely clinical and neuropsychological to include brain imaging and other 
biomarker measures [21], [30], [31]. AD diagnosis in the preclinical stage is thus supported 
by biomarkers of Aβ accumulation (CSF/PET), neurodegeneration (CSF [32]), neuronal 
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activity (functional MRI), neuronal loss (structural MRI [33]) and synaptic dysfunction 
(FDG-PET). 
Figure 1 Typical pattern of neurofibrillary progression through the course of AD 
 
Alzheimer’s association, www.alz.org 
1.2 MODULATORS OF PHENOTYPIC EXPRESSION 
Modulators of the neuropathological and neurodegenerative cascade could have either genetic 
or environmental bases affecting the rate of accumulation of brain pathology or the time at 
which the pathological changes express themselves clinically. 
Aging not only increases the risk of other comorbidities (e.g. infectious diseases, cancer, 
ischemic heart disease, stroke, type 2 diabetes and others), but also exacerbates and reinforces 
the effect of other risk factors (e.g. tobacco use, unhealthy diet, physical inactivity and 
alcohol abuse). Age is the main risk factor for AD, followed by inheritance of the 
apolipoprotein E (APOE) ε4 allele [34]. A number of risk and protective factors have been 
proposed in association with late-onset of dementia and AD [35]. The proposed risk factors 
can be categorized into vascular and metabolic: cerebrovascular lesions, diabetes mellitus and 
pre-diabetes [36], [37]; midlife positive but late-life negative: hypertension [38]; lifestyle: 
smoking and high alcohol intake; diet, saturated fat and low B vitamins; others: traumatic 
brain injury and depression. The proposed protective factors can be categorized into 
psychosocial: high levels of education and of complexity of work, rich social network and 
social engagement; lifestyle: physical activity and moderate alcohol intake; diet: 
Mediterranean diet, vitamins B6 and B12, antioxidants vitamins and vitamin D. Suggesting 
compensatory and adaptive mechanisms can modulate the effect of degenerative aging 
processes. Already today, early primary prevention starting in midlife has been implemented 
since it may be the most effective intervention [39]. 
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1.2.1 Aging and neuropathology 
Although the neuropathological hallmarks of AD can be observed in post-mortem studies of 
brains from early- and late-onset AD patients [40], individuals in the oldest age group, age 
over 80 years at time of death, without a diagnosis of dementia showed pathological features 
of AD [41]. Atrophy is considered a proxy of neuronal loss, axodendritic pruning and 
reduced synaptic density, thus reflecting both AD-like pathology and degeneration in the 
course of normal aging, which correlates with cognitive impairment and dementia [42]. Thus, 
in the oldest old, neuropathological confirmation of demented patients becomes harder since 
the same burden of pathological features may be found in persons of the same age who do not 
have dementia [43], [44]. These neuropathological features in demented patients seemed to 
remain relatively constant with increasing age, so that the ability to monitor dementia 
progression reaches a plateau [45]. Finally, the association between dementia and 
pathological features is stronger in younger patients suffering AD most probably due to the 
lack of studies on the oldest old in both normal aging and AD [46]. 
1.2.2 APOE and AD pathogenesis 
APOE protein is encoded by its homonym gene located on chromosome 19 and has three 
alleles: ε2, ε3 and ε4. The APOE ε4 allele is correlated with increased risk and earlier disease 
onset in a dose-dependent fashion [47], [48]. Heterozygous ε4 carriers have intermediate risk 
compared with homozygous carriers, while APOE ε2 has an associated protective effect and 
seems to retard AD pathology [48]. The molecular mechanisms behind this indicate the 
APOE isoforms differential regulation of both extracellular and intracellular Aβ clearance in 
the brain, which in turns regulate fibrillization of Aβ and the levels of soluble Aβ in a 
isoform-specific fashion [49], [50]. 
In MCI patients, carriers of the ε4 allele have a higher risk of rapid progression to dementia 
[51], [52]. A mechanistical explanation follows from evidence that healthy elderly carrying 
the ε4 allele show decreased cognition and decreased gray and white matter volumes in the 
medial temporal cortex [53]–[57]. Moreover, there seems to be an interaction between APOE 
and age influencing the phenotypic expression; in very-old patients carriers of the ε4 allele 
there is a decrease in sensitivity of cognitive and imaging measures [58]. 
1.2.3 Education and brain reserve 
According to the cognitive reserve hypothesis [59], individuals with higher cognitive reserve 
should be able to tolerate more severe degrees of pathology, that is, preserved cognitive 
function even when appreciable burden of pathology is present. Possible mechanisms are that 
larger brains may tolerate more loss before functional impairment occurs (passive view) [60], 
and that brain connectivity may be more diverse and efficient enhancing the ability to 
alternate compensatory brain networks (active view) [59]. Individual variation in education 
and related cognitive experiences together with individual developmental differences may 
lead to greater redundancy in neural circuits involved in cognition. This increased redundancy 
may be caused by neuroplastic effects (synaptogeneis and neurogenesis) driven by exposure 
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to enriched environments, ultimately modifying the effect of AD pathology on cognition [61]. 
However, such neural substrate for brain reserve remains elusive. Contradictory studies 
showed sMRI evidence in favor of increase reserve due to education, and lack of association 
between greater cortical thickness and higher education [62], [63]. 
1.3 MILD COGNITIVE IMPAIRMENT 
Identification of the shift between early cognitive changes associated with dementia and those 
associated with normal aging still remains elusive [64]–[70]. Thus, attention has been 
directed to the identification and characterization of a clinical population of elderly at high 
risk of developing dementia manifesting symptoms of cognitive impairment, known as mild 
cognitive impairment (MCI). However, MCI is not synonymous with early dementia since 
patients can regress, stay the same or progress to dementia. 
There is a continuum from normal aging to dementia and MCI is thought to represent the 
intermediate stage [71], [72]. MCI is a very heterogeneous group to study since diseases other 
than AD could have a prodromal stage [65], and different clinical subtypes exist [73]–[75]. 
MCI classification is determined by concepts of normal aging and dementia; as such, MCI is 
not a fixed concept, but rather a movable one that changes as dementia knowledge improves. 
Traditionally thought as a prodrome to AD, it was restricted to reflect problems in memory 
[76]. In a broader sense, the term includes any subtle impairment of cognition but insufficient 
to qualify as dementia. This may constitute impairment (decrease of at least 1.5 standard 
deviations below age norms) in one or more domains from attention, executive function, 
learning and memory, language, perceptual-motor, and social cognition. An important risk 
factor in progression from MCI to dementia is the presence of neuropsychiatric symptoms, in 
particular symptoms of depression [77], [78]. 
Medial temporal lobe atrophy present in patients with MCI seems to be a sensitive marker in 
identifying those who will progress to dementia [79]–[81]. In particular, measure of 
hippocampal volume on MRI has been proposed as a marker of incipient memory decline and 
predictor of progression to dementia [82], [83]. The most challenging distinction is between 
normal aging and MCI rather than MCI and AD, since while cognitive tests and neurological 
measures are useful, the final determination relies on the clinician’s judgment. In research 
settings, the operationalization of the criteria contributes to differences among studies. 
In AD, several studies have revealed that separate cognitive components are affected 
independently, thus giving rise to AD subgroups: memory, executive, visuospatial and 
language [30], further motivating the heterogeneous presentation of the disease and its 
prodromal stage. Thus, a combination of well-defined clinical subtypes, neuroimaging 
measures and putative etiology would be useful in prediction of progression [84]. 
1.4 EVALUATION OF COGNITIVE FUNCTION 
Numerous cognitive tests can be used for clinical and research purposes to assess cognitive 
function, monitor cognitive decline and establish dementia diagnosis. The Mini-Mental State 
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Examination (MMSE) is the most commonly used test for assessment of global cognitive 
function to screen for dementia, see Figure 2. 
The MMSE is a short and straightforward cognitive test that allows a rapid scan of cognitive 
functioning [85], screening domains of orientation, attention and memory, concentration, 
language and praxis. It was not designed to detect demented patients (for instance, mood 
assessment is excluded), and there is no substantial evidence supporting baseline MMSE 
alone identifies MCI patients who will develop dementia [86]. 
The Alzheimer’s Disease Assessment Scale – cognition (ADAS-cog) is a specialized and 
more detailed assessment of cognitive impairment in areas shown to decline in AD [87]. It 
has been frequently used as the gold standard for assessing treatment response in AD 
pharmacological trials. 
The Cognitive Dementia Rating (CDR) is a severity rating scale (0 = normal, 0.5 = 
questionable dementia, 1 = mild dementia, 2 = moderate dementia, 3 = severe dementia) and 
not a diagnostic instrument [88], [89]. Patients with a score of 0.5 may meet the criteria for 
MCI, but may also represent very mild dementia. 
 
Figure 2 Cognitive function deterioration and its relationship to AD severity 
 
Burns Alistair, Iliffe Steve. Alzheimer’s disease BMJ 2009; 338 :b158 
© 2009. Reprinted with permission from The BMJ. 
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2 IMAGING ALZHEIMER’S DISEASE 
Neuroimaging (imaging of the brain) stands as one of the most important tools to study the 
brain in vivo. It became clinically relevant and an integral part of differential diagnosis in 
brain disorders with the advent of tomographic techniques such as computed tomography 
(CT), single-photon emission computed tomography (SPECT), positron emission 
tomography (PET) and magnetic resonance imaging (MRI). When the clinical diagnosis is 
reasonably certain, routine imaging examinations are not likely to be necessary [90]. 
However, atypical cases with rapidly progressive symptoms show an increase incidence of 
neuroimaging findings and potentially treatable lesions. This idea is based on the view that 
the observed changes in cognitive function are caused by structural and functional changes in 
the brain. 
2.1 COMPUTED TOMOGRAPHY AND MAGNETIC RESONANCE IMAGING 
Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are imaging 
techniques carried out in vivo in both human and animal studies. CT is an ionizing radiation 
medical imaging technique that has commonly been extensively used in clinical routines for 
visualization of internal organs and cavities thanks to its high degree of anatomical detail 
[91]. It became an important tool to supplement x-rays and ultrasound and has been used for 
preventive medicine and screening purposes [92], [93]. CT as a routine clinical imaging 
technique enables identification and delineation of cerebral infarcts, tumors, subdural fluid 
and hydrocephalus. CT readings, visual assessment of brain scans performed by trained 
neuroradiologists, when performed on a heterogeneous group of patients with varied 
cognitive, behavioral and neurological symptoms, support clinical impressions and may 
influence treatment strategy. 
The Swedish National Guidelines for the diagnosis and management of dementia disorders 
recommend that CT/MRI should be performed in a basic workup to support medical 
treatment decisions [94]. Given the availability, cost-effectiveness and swift acquisition of 
CT imaging, it remains a widely used modality in specialist clinics for initial evaluation of 
patients with dementia [95], [96]. In a memory clinic setting, the latest multidetector row CT 
technology was shown to yield reliable radiological information comparable with that 
obtained from MRI [91]. 
MRI is a noninvasive medical imaging technique that provides better contrast of soft tissue 
than CT. It is a non-ionizing radiation technique that relies on strong magnetic fields to 
enable the visualization of internal structures with millimetric resolution. Three image 
contrasts exist: T1-weighted, T2-weighted and proton density. In studies of neuroanatomical 
structure, T1-weighted (T1-w) is used because it provides good contrast of soft tissue. The 
possibility to visualize and quantify regional and whole brain tissue shrinkage from 
structural magnetic resonance imaging (sMRI) made it the best established measurement 
for detection and tracking of AD [97]–[102]. Volume of hippocampus became the best 
validated marker of memory decline [82], being included in the diagnostic criteria for AD 
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[30], [103], and showing a distinctive pattern different from normal aging [104]–[108]. 
However its low specificity for AD makes it inappropriate to rule out other diagnosis that also 
display atrophy in the medial temporal lobes, such as those caused by non-AD dementing 
disorders: Parkinson’s disease, vascular dementia, hippocampal sclerosis, frontotemporal 
degeneration, and neurofibrillary tangle-only degeneration [109]–[112]. 
Success and acceptance of neuroimaging stems from its ability to detect structural changes 
closely related to cognitive symptoms [84], [113], such as the ventricular structures, 
hippocampus, amygdala, thalamus and entorhinal cortex [114]; also providing evidence of 
progression from MCI to AD. While quantification of atrophy requires careful and time-
consuming manual tracing, a simple and quick visual assessment by a trained 
neuroradiologist is sufficient to obtain an impression of global brain atrophy, and observe 
predictable patterns of mediotemporal and parietal atrophy, see Figure 3 [115]–[118]. 
Figure 3 Visual assessment of mediotemporal lobe atrophy (Courtesy of Lena Cavallin) 
    
T1-weighted Magnetic Resonance                        Computed Tomography 
2.2 AUTOMATED NEUROIMAGING PIPELINES 
The development of automated neuroimaging pipelines (e.g. FreeSurfer http:// 
surfer.nmr.mgh.harvard.edu, FSL http://www.fmrib.ox.ac.uk/fsl, and SPM 
http://www.fil.ion.ucl.ac.uk/spm) enables among others the processing of high-resolution 3D 
T1-w MR images and measurement of cortical thickness, cortical surface and subcortical 
volumes across multiple regions of the brain. These developments instigated a change in 
paradigm: from relying solely in regions of interest manually delineated or global/regional 
brain tissue volume, neuroscientist began the search for patterns of atrophy on sMRI by 
detecting group differences [119]–[121].  
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Quantification of cortical thickness and regional brain volumes could potentially improve 
diagnosis and early diagnosis if regions that proved more informative and sensitive to 
disease-related changes were identified, and could even outperform clinical and cognitive 
measures. The first regions to show consistent specificity of AD were located in the temporal 
lobe (hippocampus, entorhinal cortex, fusiform cortex, inferior temporal and middle temporal 
cortices), and global measures (ventricular volumes and whole-brain volume) although 
relevant were less prominent [122], [123]. Nevertheless, many cognitively normal elderly 
people display evidence of pathology that is asymptomatic, including presence of amyloid 
burden, prompting the question as to whether evidence of preclinical AD can be observed at 
very early stages of the disease process. This remains elusive, given that reductions in 
cognitive abilities like processing-speed, executive function and episodic memory are 
common among elderly people [124]–[126]. 
Unfortunately, current evidence indicates that significant age-associated decrease in global 
(whole-brain and ventricular volumes) and regional (temporal lobe and hippocampus) brain 
volumes can be observed and quantified, and there is evidence of increased acceleration of 
atrophy with increasing age [127]. After only one year, cortical (temporal and prefrontal 
cortices) and subcortical reductions, and ventricular expansions were already evident in the 
healthy elderly [128]. Thus, presence of atrophic changes does not necessarily reflect a latent 
AD process. Although in aging and AD the hippocampus and entorhinal cortex are affected, 
medial temporal lobe structures are relatively more prominently affected in AD [129]. In 
normal aging, the medial temporal lobe structures are relatively spared and most of the age-
associated cortical atrophy is most prominent in prefrontal, lateral parietal and sensorimotor 
regions [130]. Since brain atrophy in AD-prone regions can be seen in normal aging, early 
diagnosis of dementia with a high sensitivity will most likely result in low specificity. Age 
inevitably affects brain structures independently of AD, not necessarily related to an ongoing 
neurodegenerative disease, resulting in part of late life cognitive decline left largely 
unexplained [131]. 
Group-based univariate statistics at regional or voxel level offer limited sensibility when 
differences between populations are due to complex combinations of several brain structures. 
While it may be possible to say that Alzheimer’s patients have smaller hippocampi than 
controls, it is difficult to deduce that an individual is in the early stages simply by examining 
hippocampal volume, or any given number of structures in this fashion. No information at the 
individual level is obtained. Hence, a growing interest in statistical learning methods to 
overcome the limits of univariate analysis and capture relationships among all measures has 
begun. 
2.3 INDIVIDUAL CLASSIFICATION BASED ON STATISTICAL LEARNING 
Eventually, the diagnostic utility of sMRI was demonstrated after the individual 
classification of Alzheimer’s disease versus cognitively normal aging became feasible and 
reliable. It was the integration of neuroscience, statistical learning and neuroimaging that led 
to the application of support vector machines to MRI for individual diagnosis [132]. This first 
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study successfully classified gray matter from T1-w MR scans of pathologically proven AD 
patients from those of cognitively normal elderly individuals (up to 96% accuracy). A 
number of studies followed for AD classification, MCI classification and progression, and 
normal aging progression [133]–[143]. 
Similarly to the group-based analysis, variables of importance for the classification of AD 
and cognitively normal individuals were medial temporal lobe structures (hippocampus, 
amygdala, entorhinal cortex, parahippocampal gyrus, inferior and superior temporal gyri, 
cingulum), isthmus cingulate and ventricular volumes as reported for OPLS [144], [145], 
SVM [135]–[137] and linear discriminant analysis [146]. 
Moreover, the use of statistical learning techniques not only allows the integration of 
information from multiple brain structures and combination of volumes and cortical thickness 
measures in a principled manner. Statistical learning techniques also allow the creation of a 
single quantitative value for each individual with discriminative power reflecting the presence 
of disease-like patterns of brain atrophy [135], [136], [147] and age-associated patterns of 
brain atrophy [138]. The high discriminative power of disease-specific patterns of atrophy is 
not surprising, what has become of greatest research value has been the individual 
discrimination of MCI from cognitively normal individuals carried out in cross-sectional and 
longitudinal studies [137], [148], [149]. Structural neuroimaging has shown that there are 
significant individual differences in cognitive decline, progression to AD and 
neurodegeneration [150], bringing new insights into different pathophysiological processes 
underlying AD [151]. 
The marriage between statistical learning and neuroimaging gave birth to an explosion of 
statistical methods being applied based on sMRI to overcome not only statistical limitations 
but also methodological issues such as multicenter studies, multiscanner acquisitions, 
multiprotocol scanning, and multiple data fusion [152], [153]. The quest for imaging 
neuropathology in vivo was initially driven by better visualization, then more accurate 
measures and better statistics and has finally been driven by data integration and individual’s 
risk estimation and individualized diagnosis. 
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3 STATISTICAL LEARNING 
Begot by the need of experimental scientists to fit theoretical models from limited noisy data 
and make predictions, linear regression was realized by the method of least squares [154]. 
Soon after, many other methods based on linear models were proposed, such as linear 
discriminant analysis, logistic regression and generalized linear models [155], [156]. 
Advances in computing technology made it possible to introduce non-linear models like 
classification and regression trees, and generalized additive models [157], [158]. 
3.1  ESTIMATION OF A FUNCTIONAL RELATIONSHIP 
Modeling is part of most research devoted to quantify relationships among variables of some 
process. Quantification of a process may mean determining the degree of association between 
a dependent variable and explanatory variables, or estimating the many parameters of a 
theoretical mathematical model for a system. For instance, the most general relationship 
between a dependent variable Y and several explanatory variables X (X = X1, X2, X3, …) can 
be mathematically expressed as 
 𝑌 = 𝑓(𝑋) + 𝜖 4.1 
A fixed and unknown function f represents the systematic information that the explanatory 
variables provide about the dependent one; and ϵ is a random error term with zero mean. The 
whole purpose of statistical learning is to estimate a functional relationship (Equation 4.1) 
from the observed data, in order to make predictions and inference. 
Statistical learning methods can be classified as either parametric or non-parametric. 
Parametric methods are characterized by assuming a priori a functional form, simplifying the 
estimation problem to that of fitting a set of parameters. While non-parametric methods avoid 
the assumption of a particular functional form covering a wider range of relationships among 
the variables. 
Variables can be classified as either quantitative (continuous) or qualitative (categorical). 
Examples of quantitative variables include age, height and weight, while examples of 
qualitative variables include gender, diagnosis and marital status. Statistical learning 
problems with a quantitative dependent variable are commonly referred to as regression 
problems, while those involving a qualitative one are referred to as classification problems. 
The accuracy of a prediction depends on two types of error: one is reducible error, given that 
the functional relationship is unknown and must be estimated. This error can be diminished 
by choosing a suitable function. The second is irreducible error stemming from the fact that 
the dependent variable is assumed to be a random variable, generating variability that does 
not depend on the explanatory variables, thus this cannot be estimated, and it affects 
prediction. 
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Statistical learning methods are designed to decrease the reducible error by a process called 
learning. Formally, learning reduces to an optimization problem: find the optimal functional 
relationship that ensures a good representation of the data without modeling the irreducible 
error. Associated with every chosen function, there is an expected risk 𝑅[𝑓] that the estimated 
functional relationship will also model this error. Learning aims at decreasing this expected 
risk, also called generalization error, to a minimum. The expected risk captures the average 
discrepancy between predictions and true values on unseen data not used during the learning 
process, thus intuitively assessing the quality of the modeling. Discrepancy is measured by a 
suitable function for our particular learning problem, known as the loss function 𝐿(𝑌, 𝑓(𝑋)). 
Mathematically, the expected risk corresponds to the computation of the expectation 
(average) of the loss function. 
 
𝑅[𝑓] = ∫ 𝐿(𝑌, 𝑓(𝑋))𝑑𝑃(𝑋, 𝑌) 
4.2 
A problem associated with the learning processes just described originates from observing 
that the original formulation of the expected risk (Equation 4.2) demands unseen data, 
independent from the one used for learning. In reality, when data is scarce, the risk is 
calculated by minimizing the loss function on the sample data. This risk computed on the data 
also used for learning is known as the empirical risk or training error. In practice, for some 
cases there are large deviations between the empirical and expected risks due to noisy data 
and because a theoretical model will never perfectly model a real-life process. 
One idea that originated to tackle this problem starts by defining a guaranteed risk 𝑅𝑔𝑢𝑎[𝑓] 
[159]. A guaranteed risk is an upper bound on the expected risk; it guarantees that with 
probability (1 - δ), the expected risk will not exceed a fixed quantity. 
 𝑅[𝑓] ≤ 𝑅𝑔𝑢𝑎[𝑓, 𝛿] 4.3 
The Vapnik-Chervonenkis theory shows that when learning from a finite amount of training 
data, the minimization depends on both the training error and the statistical complexity of the 
function class, or capacity [160]. The VC theory predicts that if the capacity of the function 
class is restricted so that it is small enough in relation to the available amount of data, i.e. 
optimal capacity matched to the size of the training set, then for all functions of that class: 
with probability of at least 1 – δ, the expected risk is at most equal to the guaranteed risk. 
3.2 LINEAR REGRESSION 
In the context of empirical science, an experimenter trying to understand a phenomenon may 
measure various quantities in a system and attempt to predict dependent from explanatory 
variables. If the experimenter has sufficient evidence to assume a priori a linear relationship 
exists between the variables (functional form), then linear regression suffices to determine 
linear relationships between a set of (quantitative) dependent variables and a set of 
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explanatory variables. This method produces the best linear fit and is known as ordinary 
least squares regression. In the context of linear regression, multivariate regression refers to 
the case where the goal is to form relationships between several dependent variables and 
several explanatory variables; and univariate regression when there is only one dependent 
variable and several explanatory variables. 
Mathematically, a linear model can be expressed as 
 𝑓(𝑋) = 𝛽0 + 𝛽1𝑋1 + 𝛽2𝑋2 + ⋯ 4.4 
Where 𝛽 = 𝛽0, 𝛽1, 𝛽2, ⋯ are the parameters to be estimated from the available data by a 
statistical learning method. Associated with every model, the error term ϵ prevents a perfect 
prediction of dependent from explanatory variables. In particular, assuming a linear model, 
the general linear relationship becomes 
 𝑌 = 𝛽0 + 𝛽1𝑋1+𝛽2𝑋2 + ⋯ + 𝜖 4.5 
In the context of regression, the most common and intuitive loss function is the squared loss 
of residuals 𝐿(𝑌, 𝑓(𝑋)) =  (𝑌 − ?̂?)
2
. Defining, ?̂? as the prediction of dependent from 
explanatory variables, and the residual sum of squares, 𝑅𝑆𝑆 = 𝑒1
2 + 𝑒2
2 + ⋯ + 𝑒𝑛
2, where 
𝑒𝑖
2 = (𝑦𝑖 − ?̂?𝑖)
2. RSS measures the amount of variability left unexplained after performing 
the regression. One finds that the least squares approach to linear regression is a realization of 
statistical learning that chooses to minimize the squared loss of residuals. 
Measuring a large of number of explanatory variables is often done in the hope that some of 
them may contain relevant variability to explain the process of interest even if some make 
little contribution. However, having a large number of variables may introduce systematic 
variation unrelated to the dependent variable, and may often constitute the major part of the 
observed variation. Moreover, in the case of multicollinearity (two or more explanatory 
variables related to one another) or a small number of observations and a large number of 
explanatory variables, the regression problem becomes overdetermined. As the number of 
explanatory variables increases, the data appear cloudy, unclear and redundant, making it 
difficult to determine how each variable is separately associated with the dependent one. 
3.3 PRINCIPAL COMPONENT ANALYSIS 
A simple and non-parametric standard tool in data analysis, principal component analysis 
(PCA), solves this problem by extracting relevant information by reducing complex data to a 
lower dimension. PCA helps identify a set of variables, also known as components, that 
optimally capture the variability present in the explanatory variables. One of the main 
assumptions behind this technique is that large variance corresponds to the dynamics of 
interest while low variance represents noise. 
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A rationale for dimension reduction, that is producing a number of components less than the 
number of explanatory variables, is as follows. An equation with many components is 
typically more flexible than one containing fewer, with the disadvantage that estimating its 
components would be more easily influenced by noise (random errors) present in the data. 
That is, having more components allows for a better fit of the data, at the expense of noise 
also being modeled. When the model is applied on unseen data to make predictions, it turns 
out that more mistakes are made, bigger generalization error, than applying a model with 
fewer components less influenced by noise. 
3.4 PARTIAL LEAST SQUARES 
When the goal is to predict a set of dependent variables and the number of observations is 
small compared to the number of explanatory variables or there is multicollinearity, a 
simultaneous decomposition, dimension reduction, of explanatory and dependent variables 
might be optimal. Partial least squares (PLS) regression finds components that best predict 
the dependent variable. Each component is a linear combination of all explanatory variables, 
and relates them to the dependent variable using ordinary least squares regression. 
PLS regression generalizes PCA and multiple linear regression by forming components that 
capture most of the variability that is useful for prediction, while reducing the dimensionality 
of the regression by using fewer components than the number of explanatory variables. Each 
component is constrained to be uncorrelated with each other, that is, they are said to be 
orthogonal to each other, solving the multicollinearity problem. However, the issue of 
deciding the optimal number of components to keep remains; therefore it is necessary to 
apply additional customized criteria. 
3.5 ORTHOGONAL PLS 
A method related to PLS, orthogonal PLS (OPLS), extends PLS by applying cross-validation  
as a customization criterion to determine the optimal number of components and, by 
separating the predictive and orthogonal components, to facilitate model interpretation [161]–
[165]. OPLS unlike PLS keeps the correlated variation, related to class separation, in the first 
predictive component. And all uncorrelated variation, unrelated to class separation, in 
orthogonal components. The rationale is that by removing uncorrelated variation prior to data 
modeling, interpretability improves and the predictive ability should improve as well. In 
cases where large uncorrelated variation is present, PLS is forced to include all that variation 
in each PLS component, while OPLS extracts all correlated variation into one PLS 
component. 
3.6 LINEAR CLASSIFICATION 
So far, this presentation has focused on regression problems, the other major category is 
classification problems. Most concepts and ideas translate directly to classification problems 
where the dependent variable is no longer quantitative but qualitative; the objective being to 
estimate a function that predicts class label. The average number of misclassifications 
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intuitively appears as an appropriate loss function to compute the expected risk for 
classification problems. Thus, the loss function 𝐿(𝑌, 𝑓(𝑋)) should correspond to a function 
that indicates when a misclassification is done 𝑌 ≠ ?̂?. This simple function is appropriately 
called the indicator function 𝐼(𝑌, 𝑓(𝑋)) 
 
𝐼(𝑌, 𝑓(𝑋)) = {
1 𝑖𝑓 𝑌 ≠ ?̂?
0 𝑖𝑓 𝑌 = ?̂?
 
4.6 
In classification problems, correlated variation from a trained OPLS model corresponds to 
variation that separates the groups and non-correlated variation corresponds to variation that 
combines the groups [166]. 
An algorithm to solve linearly separable classification problems was devised by applying the 
idea of optimal capacity tuning by constructing hyperplanes, also known as linear classifier: 
 𝑓(𝑋) = 𝑤1𝑋1 + 𝑤2𝑋2 + ⋯ + 𝑏 4.7 
Notice the similarity to Equation 4.4, they are identical since a linear relationship is also 
assumed here. It was recognized that finding the parameters 𝑤1, 𝑤2, ⋯ , 𝑏 that maximizes the 
margin is equivalent to finding training examples closest to the class boundary. Maximizing 
the margin between training examples and class boundary is equivalent to optimizing the 
capacity of the classification function to match the size of the training set. Those examples 
closest to the class boundary are called the supporting patterns, or support vectors, of the 
decision function. The training algorithm for optimal margin classification is known as 
Support Vector Machines (SVM) [167]. Although multicollinearity is not a problem for this 
method, the presence of noise can make the boundary between the classes overlap, rendering 
the problem non-separable. In such cases, the algorithm can be modified and allow some 
support patterns to be misclassified [168]. 
3.7 MAXIMUM-LIKELIHOOD ESTIMATION 
A fundamental problem in statistical inference, namely that of recovering the parameters for 
a given parametric statistical distribution, is briefly presented. The best known criterion for 
parameter estimation is known as maximum-likelihood estimation (MLE) [169]. MLE can be 
formally stated as maximizing the expected log-likelihood of the data, such that when the 
resulting set of parameters are plugged into the model it yields maximum probability for the 
given data. MLE is very fundamental since any variable can be thought of as a random 
variable following a (un-)known statistical distribution. 
Maximum-likelihood mixture estimation (MLME) finds the mixture of n distributions from a 
specified parametric probability family that best fits the expected log-likelihood of the data. 
The best-known statistical technique for MLME is the Expectation Maximization (EM) 
algorithm. The algorithm converges to a local maximum by iteratively increasing the log-
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likelihood of the data to the model; at convergence the log-likelihood remains constant. EM 
works by iteratively applying Expectation and Maximization steps. In the Expectation step, 
the expected value of the data for each model given the current parameters is computed. In 
the Maximization step, the current parameters are updated based on maximum likelihood of 
the data. 
The most common family of statistical distributions is the exponential family. Members of 
this family include Gaussian, Poisson, Binomial and Multinomial distributions [170]. In the 
Maximization step of the EM algorithm, the expected log-likelihood is maximized to obtain a 
better fit of the parameters. For a regular exponential family this equates to finding the unique 
parameter that minimizes the expected value of a corresponding regular Bregman divergence 
[171], [172]. And it has been shown that this minimizer is just the expectation of the random 
variable X [172]. Thus, the problem of MLE for a given regular exponential family 
corresponds to minimizing the expected Bregman divergence of the family, simplifying the 
computationally intensive maximization step of the EM algorithm and resulting in a general 
soft-clustering algorithm [172]. 
3.8 CLUSTERING 
Clustering refers to a broad class of methods for discovering unknown subgroups in data. In 
this setting there are only explanatory variables, and since there is no associated dependent 
variable, the previous classification and regression methods are not applicable. Clustering 
seeks to partition the datainto distinct groups, where members of a group are similar to each 
other, while members of different groups are different, dissimilar to each other. Clustering 
simplifies data: from a sample of N observations to a sample of M subgroups. The 
optimization problem can formally be defined as minimizing the within-cluster variation. 
Among the different categories of techniques employed in clustering, there are methods that 
operate on a dissimilarity matrix, such as sum-of-squares methods; and mixture models, 
which model the probability density function as a sum of individual statistical distributions, 
such as clustering applying MLME. 
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4 AIMS OF THE THESIS 
 
The main interest of this thesis was the analysis and individual classification of Alzheimer’s 
disease, MCI and normal aging populations based on structural neuroimaging. In particular, 
we aimed to evaluate and validate automated tools that have a potential diagnostic role based 
on structural image analysis of the brain. 
Development of classification methods requires several methodological choices. The specific 
aims of this thesis were: 
Study I To evaluate different combinations of brain measurements and 
different normalization approaches to determine the optimal choice for 
individual classification of AD and prediction of MCI conversion at 
one-year follow-up. 
Study II To evaluate different statistical techniques for individual classification 
of AD and prediction of MCI conversion one year later, and the effect 
of age, education and APOE genotype to determine the optimal 
classification algorithm. 
Study III To characterize the longitudinal information condensed into a 
structural index derived from a statistical classifier to evaluate its 
validity as marker of atrophy change and disease progression over a 
year. 
Study IV To develop and validate an automated CT-based segmentation 
algorithm for quantification of total intracranial volume that 
demonstrates reliability, reproducibility and robustness. 
Preliminary 
studies 
Apply the proposed segmentation algorithm in a big sample of 
cognitively normal and demented elderly individuals, and extend the 
proposed methodology to obtain estimates of brain tissue and CSF 
volumes. 
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5 METHODOLOGY 
5.1 ETHICAL CONSIDERATIONS 
These studies were approved by ethical review boards in each participating country, and the 
participants have been informed and given written consent for inclusion. 
5.2 STUDIES I-III 
Subjects 
Data was downloaded from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
database (www.loni.ucla. edu/ADNI, PI Michael M. Weiner). A total of 699 subjects were 
included in the study (AD = 187, MCI = 287 and cognitively normal = 225). ADNI was 
launched in 2003 by the National Institute on Aging (NIA), the National Institute of 
Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Administration (FDA), 
private pharmaceutical companies and non-profit organizations, as a $60 million, 5-year 
public–private partnership (www.adni-info.org).  
Data also originated from the AddNeuroMed project, part of InnoMed (Innovative Medicines 
in Europe), a European Union program designed to make drug discovery more efficient. A 
total of 348 subjects were included in the study (AD = 119, MCI = 119 and cognitively 
normal = 110); a subsample of 214 subjects with a one-year follow-up was also included (AD 
= 62, MCI = 73 and cognitively normal = 79). The project is designed to develop and validate 
novel surrogate markers in AD and includes a human neuroimaging strand [173], [174] 
which combines MRI data with other biomarkers and clinical data. Data was collected from 
six different sites across Europe: University of Kuopio, Finland, University of Perugia, Italy, 
Aristotle University of Thessaloniki, Greece, King's College London, United Kingdom, 
University of Lodz, Poland, and University of Toulouse, France. 
MRI data 
Data acquisition for the AddNeuroMed study was designed to be compatible with the ADNI 
project [175]. The imaging protocol for both studies included a high resolution sagittal 3D 
T1-w Magnetization Prepared Rapid Acquisition with Gradient Echo (MPRAGE) volume 
(voxel size 1.1 × 1.1 × 1.2 mm
3
) and axial proton density/T2-weighted fast spin echo images. 
The MPRAGE volume was acquired using a custom pulse sequence specifically designed for 
the ADNI study to ensure compatibility across scanners. Full brain and skull coverage was 
required and detailed quality control carried out on all MR images according to the 
AddNeuroMed quality control procedures [173], [174]. 
Inclusion criteria 
For ease of comparison, the inclusion criteria for subjects enrolled in the ADNI and 
AddNeuroMed projects are presented in Table 1. 
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Table 1 Inclusion criteria   
 
ADNI AddNeuroMed 
Alzheimer's disease 
  MMSE 20-26 12-28 
CDR > 0.5 > 0.5 
GDS < 6 - 
Age - > 65 
ADRDA/NINCDS Yes Yes 
DSM-IV - Yes 
   Mild cognitive impairment 
  MMSE 24-30 24-30 
CDR 0.5 0.5 
GDS < 6 <= 5 
Age - > 65 
   Cognitively normal 
  MMSE 24-30 - 
CDR 0 0 
ADNI = Alzheimer’s Disease Neuroimaging Initiative, MMSE = mini mental state examination, CDR = 
cognitive dementia rating, GDS = geriatric depression scale, ADRDA = Alzheimer’s disease and related 
disorders association, NINCDS = national institute of neurological and communicative disorders and stroke, 
DSM = diagnostic statistical manual. 
 
Automated neuroimaging pipeline 
FreeSurfer is an image analysis suite that takes as input one or several T1-w images. It 
removes all non-brain tissue before automatic segmentation of the subcortical white matter 
and deep gray matter volumetric structures, including amygdala, hippocampus, caudate, 
putamen and ventricles. After creation of a cortical model further processing of the cerebral 
cortex produces representations of cortical thickness not restricted to the voxel resolution of 
the original data, thus capable of detecting submillimeter differences. These procedures have 
been validated and are properly documented in its website 
(http://surfer.nmr.mgh.harvard.edu). 
Pre-processing of structural measures 
Variables were mean centered (zero mean) and scaled to have unit variance by dividing it by 
its sample standard deviation. Scaling may be necessary since the variables with highest 
variance would influence the performance of techniques based on squared Euclidean 
distance. Given that the average distance measure over all pairs of observations is 𝐸[𝐷] =
1
𝑁2
∑ ∑ 𝐷(𝑋𝑖, 𝑋𝑗)𝑗𝑖 = ∑ 𝐸[𝑑𝑘]𝑘 , where 𝐸[𝑑𝑘] =
1
𝑁2
∑ ∑ 𝑑𝑘(𝑋𝑘
𝑖 , 𝑋𝑘
𝑗)𝑗𝑖  is the average distance 
on the k-th variable. For the squared Euclidean distance, the average distance on the k-th 
variable becomes 𝐸[𝑑𝑘] =
1
𝑁2
∑ ∑ (𝑋𝑘
𝑖 − 𝑋𝑘
𝑗)
2
= 2 ∙ 𝜎2𝑗𝑖 , that is twice the sample estimate of 
the variance of the k-th variable. The relative importance of each variable is proportional to 
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its variance. Scaling every variable by dividing it by the sample standard deviation causes 
each of them to contribute equally. 
Figure 4 Illustration of statistical learning techniques considered in this thesis. 
  
Decision trees Orthogonal partial least squares 
 
 
Artiticial neural networks Support vector machines 
Statistical learning techniques 
Four classification techniques were considered taking all structural measures derived from 
FreeSurfer as explanatory variables and clinical diagnosis as dependent variable (demented 
vs. non-demented), see Figure 4. 
An implementation of decision trees (Trees) part of the WEKA machine learning software 
was used [176]. This family of techniques works by finding arbitrarily complex Boolen 
functions (YES/NO): a decision tree breaks the classification problem down into a set of 
choices (if-then rules). A greedy algorithm builds the tree by choosing the most informative 
variables based on information theory criteria [177]. 
An implementation of artificial neural networks (ANN), multilayer perceptron, part of the 
WEKA machine learning software was used [176] . An artificial neural network is a non-
linear statistical model inspired from the nervous system. Taking a neuron as the processing 
unit of the brain, Rosenblatt proposed a hypothetical nervous system: the perceptron [178]. 
The implementation of the Support Vector Machines (SVM) based on the LIBSVM library 
was used [179]. This implementation solves the soft-margin classifier and allows for non-
linear mapping of the input variables to a higher dimensional space thanks to the dual kernel 
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representation, allowing for misclassification and modeling of non-linear relationships among 
the input variables. 
The OPLS implementation included in the statistical package SIMCA was used (Umetrics 
AB, Umeå, Sweden) as a supervised (classification) multivariate data analysis method. 
Model validation via cross-validation 
Cross-validation is a statistical technique for validating a predictive (classification) model 
which involves constructing a number of parallel models. Each time a new model is created, 
part of the data is left out to estimate predictive accuracy on unseen data; this process is 
repeated for all possible permutation of the data. A 10-fold cross-validation was applied 
through all studies [180]. 
5.3 STUDY IV 
Subjects 
Eighteen patients (8 women and 10 men; mean age of 73 years) referred to a local Memory 
Clinic (Karolinska University Hospital, Huddinge) were retrospectively selected. From all 
who had undergone imaging examination of the brain in the context of memory investigation, 
we selected those who were scanned using both CT and MRI, or were scanned twice the 
same day using CT. Patients with other pathologies, such as intracranial tumors or infarcts 
were excluded. 
CT and MRI data 
The imaging protocol included an axial CT scan (GE Medical Systems, LightSpeed VCT) 
without intravenous contrast (detector area, 20 mm x 0.625 mm; voxel size, 0.4199 x 0.4199 
x 2.5 mm
3
; effective radiation dose, 1.7 mSv). The MRI acquisition (1.5 Tesla scanner; 
Siemens, Avanto) included a T1-w MPRAGE coronal pulse sequence (TR, 1910 ms; TE, 
3.14 ms; flip angle, 15 degrees; voxel size, 0.449 x 0.449 x 1.4 mm
3
). 
All subjects were scanned using the same protocol. Full coverage was required with at least 
one slice totally above and one totally below to ensure full coverage of total intracranial 
cavity. As quality control, each scan was visually inspected to assess whole brain coverage 
and that no major artifacts were present. 
Hounsfield scale 
The Hounsfield Unit (HU) scale is a linear transformation of the original linear attenuation 
coefficient measurement. One advantage of using a normalized unit system like the HU scale 
is that irrespective of the machine and energy used, the radiodensity of water is defined as 0 
HU, and that for air as -1000 HU. Hence, every substance has a unique CT number in the 
Hounsfield scale. Table 2 shows examples of common substances and its corresponding 
value in the HU scale. 
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Table 2 Hounsfield scale 
Substance HU 
Air -1000 
Lung -500 
Fat -100 to -50 
Water 0 
CSF +15 
WM +20 to +30 
Blood +30 to +45 
GM +37 to +45 
Bone +3000 (dense bone) 
CSF: cerebrospinal fluid, WM: white matter, GM: gray matter. 
 
Automated MRI pipeline 
Structural MRI images were skull-stripped using the Brain Extraction Tool (BET) from FSL. 
This method uses a deformable surface model that is fitted to the brain surface. The original 
images were cropped using fslroi from FSL to remove the neck. The pre-processed images 
were fed into sienax from FSL for neuroimaging segmentation. 
Automated CT segmentation algorithm 
Automated segmentation on CT was based on soft-clustering the accumulated histogram of 
pixel’s intensity values by fitting a mixture of two binomial distributions applying MLME. 
The following algorithm was implemented based on open-source libraries for reading 
DICOM medical files (Grassroots DICOM – http://gdcm.sourceforge.net), programming real-
time computer vision applications (OpenCV – http://opencv.org) and writing interpreted 
scripts (Lua – http://www.lua.org). 
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Proposed algorithm (see Figure 5): 
1. Axial CT images were read and pixel intensity information extracted (Step I). 
2. Two new images are derived based on hard thresholding: (1) brain tissue and 
cerebrospinal fluid (CSF) information with pixel intensities in the range -50 to 200 
HU, and (2) bone information with pixel intensities greater than 200 HU. 
3. The interior of the skull is traced from each slice by applying binary operations. 
Starting at the level of the eyeballs, information from the previously traced slice was 
used to estimate a region-of-interest and correctly extract the brain tissue, and at the 
same time remove parts of the eyeballs and connecting veins. 
4. The intensity information from all slices is aggregated into a single histogram 
representing the probability distribution of all pixel’s intensity (within the range -50 to 
200 HU) composed of two separate frequency curves: CSF and brain tissue (Step II). 
5. Maximum-likelihood mixture estimation is applied to obtain the parameters of a 
mixture of two binomial distributions resulting in a robust estimation of the maximum 
and minimum intensities with a significant probability of belonging to the fitted 
distribution (Step III). 
6. All pixel intensity is restricted to lie between these minimum and maximum 
intensities and the resulting mask is eroded and dilated using an elliptical structural 
element (Step IV). 
Statistical analysis 
Agreement was assessed by quantification of volume differences and average volumes for 
repeated measures as part of a Bland-Altman analysis [181], and illustrated in a Bland-
Altman plot; statistical significance of the presence of bias was computed based on a one-
sample Student’s t-test [182]. 
The degree of correlation was determined by computing the Pearson’s correlation coefficient 
to test for linear correlation between the average volumes among different segmentation 
approaches. 
5.4 PRELIMINARY STUDIES 
Subjects 
Ten patients from the previous study who underwent imaging examination of the brain in the 
context of memory investigation, and who were scanned twice the same day using CT were 
selected for validation of a regional segmentation algorithm. 
Additional data also included two hundred forty-eight subjects (24 demented and 224 non-
demented; 147 women and 101 men) of 85 years-of-age, born between 1923 and 1924, part 
of a population-based cohort (Gothenburg, Sweden) who had undergone CT imaging 
examination of the brain. 
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CT data 
The imaging protocol included an axial CT scan (General Electric’s Medical Systems, 
LightSpeed VCT) without intravenous contrast (detector area, 20 mm x 0.625 mm; voxel 
size, 0.4199 x 0.4199 x 5.0 mm
3
; effective radiation dose, 1.7 mSv). 
All subjects were scanned using the same protocol. As quality control, each scan was visually 
inspected to assess whole brain coverage and that no major artifacts were presents. 
Automated CT regional segmentation algorithm 
The segmentation algorithm proposed in the previous section works by modeling the 
accumulated intensity histogram as a mixture of two binomial distributions: one modeling 
CSF and another modeling brain tissue (Step III). Successful MLME results in the estimation 
of four parameters: two constants that weight the contribution from each distribution, and two 
parameters that correspond to the expectation parameter or probability for each binomial 
distribution. 
Thus, as result of the MLME we obtain a probability model for the intensity distribution 
considering two random variables: pixels from CSF and pixels from brain tissue. Based on 
the naïve Bayes classification rule: for each intensity value select the distribution that is most 
probable and assign that class label (Step V). The algorithm is extremely efficient since only 
intensity values are considered, thus it is enough to construct a look-up table to segment a 
whole image. 
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6 RESULTS 
Development and longitudinal validation of a structural index from statistical models of 
AD-like patterns of atrophy (Studies I-III)  
Several brain measures obtained by automated segmentation and parcellation of sMRI brain 
scans were used to train discriminative models for individual prediction of AD and 
conversion from prodromal stages. Among the methodological considerations faced when 
training discriminative models covered in these studies were: an optimal normalization 
strategy, an optimal combination of structural measures, the best discriminative learning 
technique and the influence of APOE genotype. A structural index reflecting information 
about AD-like of atrophy was derived from a baseline model based on the OPLS 
classification algorithm. And the temporal evolution of the derived index was assessed using 
one-year longitudinal information. 
Optimal normalization strategy  
In order to achieve optimal discriminative patterns of atrophy, brain measures need to be 
properly normalized. In study I, a significantly better discrimination of AD patients from 
cognitively healthy individuals was obtained for raw cortical thickness measures compared to 
normalized measures: 85.5% accuracy for raw measures, 83.5% accuracy for normalization 
by ICV and 83.7% accuracy for normalization by mean cortical thickness. In single region 
analysis, significantly better results were obtained when cortical volumes were normalized: 
83.5% accuracy for normalization by ICV vs. 81.8% accuracy for raw volumes. 
Optimal combination of brain structures 
The best hierarchical model combining two different measures incorporated cortical and 
subcortical measures: 89.8% accuracy for subcortical volumes + cortical thickness, and 
88.6% accuracy for subcortical volumes + cortical volumes. Normalization had no effect on 
these models. Combining three different measures did not significantly improve the 
prediction accuracy either, although the best overall model included raw cortical thickness + 
normalized cortical volumes + normalized subcortical volumes, resulting in 91.5% accuracy. 
Additionally, for individual MCI prediction of conversion to AD at 18-month follow-up, a 
hierarchical model combining subcortical volumes + cortical volumes or cortical thickness 
measures resulted in 77% of the MCI converters (MCI-c) correctly classified as AD. 
Best discriminative learning technique 
Optimal discrimination can also be influenced by the technique chosen to build statistical 
models. In study II, a baseline model was created based on the optimal normalization strategy 
and optimal combination of structural measures found in study I. Further, this model was 
used to compare the discrimination ability of different statistical learning techniques. The 
resulting discriminative models seemed to be equally accurate: 81.8% accuracy for Trees, 
84.9% accuracy for ANN, 83.6% accuracy for SVM, and 84.5% accuracy for OPLS. 
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Likewise, classification of MCI-c as AD resulted in good discrimination: 85.7% for Trees, 
81.0% for ANN, 85.7% for SVM, and 81.0% for OPLS. As expected, the hippocampus was 
the top ranked relevant feature for classification irrespectively of the classifier or whether 
feature selection was performed. 
Addition of modulators of phenotypic expression 
Further, addition of age, education level or APOE phenotype to the baseline model did not 
significantly improved prediction accuracy. Rather, if age was added to the model the 
performance of Trees became significantly reduced (P < 0.005), and if education was added 
to the model the performance of Trees was also significantly reduced (P < 0.05).  Moreover, 
selecting the top most relevant measures did not result in better accuracy, nor did treating the 
variables differently using multi-kernel learning or hierarchical learning significantly improve 
performance when compared to the baseline model. 
AD-like patterns of atrophy condensed into a structural index 
From study I and II we showed that it was possible to build statistical models to find highly 
discriminative patterns of atrophy. But an atrophy score capturing the signature of these AD-
like patterns of atrophy would facilitate clinical interpretation. In study III, the OPLS 
classification algorithm was trained on the baseline model to produce a structural index 
reflecting information about AD-like patterns of atrophy. We demonstrated high 
discrimination of AD patients from cognitively normal individuals at baseline: 84% 
specificity and 91% sensitivity. We observed that the AD-like patterns consisted of several 
relevant brain regions such as: the hippocampus, entorhinal cortex, amygdala, temporal lobe, 
superior temporal gyrus, inferior lateral ventricle, middle temporal gyrus, fusiform gyrus, 
inferior temporal gyrus and parahippocampal gyrus. 
Temporal evolution of a structural index 
As expected for an index reflecting AD-like atrophy, the AD group had the highest scores, 
followed by MCI-c, stable MCI and the cognitively normal group. All diagnostic groups 
showed higher scores over time, although AD patients showed the fastest rate (One-way 
ANOVA P = 0.044). The increase in scores over time improved classification accuracy due 
to a better sensitivity at the expense of reduced specificity: at baseline the sensitivity was 
81% and the specificity was 90%; at one-year the sensitivity was 92% and the specificity was 
75%. The oldest old individuals with normal cognition showed a high frequency of scores 
typical of AD-like atrophy (> 0.5) and had a significantly faster rate of cognitive (MMSE, 
Mann-Whitney p = 0.05) and structural (Mann-Whitney p = 0.028) decline. MCI patients that 
converted to AD within one-year presented scores non-significantly different from the AD-
group (two-sided T-test p = 0.76), with the exception of three patients with normal scores (< 
0.5). Finally, stratification of MCI patients into carriers vs. non-carriers of the APOE ε4 allele 
showed that carriers had higher scores (P = 0.013) and were more cognitively impaired 
compared to non-carriers (ADAS1, P = 0.017; CDR-sum, P = 0.013). 
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Intracranial volume estimation from Computed Tomography scans (Study IV) 
Although MRI offers better brain tissue contrast, and is the preferred research imaging 
technique, CT is today widely used in routine clinical investigations. Since ICV remains a 
morphological measure of interest, in study IV we aimed to develop and validate an 
automated segmentation algorithm to estimate ICV from CT scans. 
Our developed automated segmentation algorithm achieved successful segmentation to the 
degree of intensity variability seen in our sample, and good agreement with manual 
delineation set as gold standard (Student t-test one-tailed, paired means, P = 0.011). 
Moreover, the developed algorithm showed less variability in the estimation of ICV 
compared to manual tracing (F statistics = 0.004, P < 10
-7
). There was a high correlation 
between our segmented volumes on CT and those segmented from MRI (Pearson’s r = 0.92; 
linear regression R
2
 = 0.84). We also observed low variability in volumes estimated on 
repeated acquisitions: a Bland-Altman analysis showed a non-significant bias of -1.5 mL 
(one-sample Student’s t-test, one-tail, p = 0.76). 
Preliminary studies: estimation of brain and CSF volumes from brain parenchyma 
In study IV we presented a segmentation algorithm designed to successfully estimate ICV by 
modeling the intensity information in CT head scans. However, ICV alone does not offer any 
relevant diagnostic information. Both brain and CSF volumes are clinically relevant measures 
of cognition and the ratio between them appeared to be a sensitive measure of atrophy [183]–
[185]. 
Validation of regional segmentation of brain parenchyma 
In this preliminary study we aimed to extend the algorithm presented in study IV to obtain 
estimates of brain and CSF volumes from segmented brain parenchyma. As an initial 
approach we tested the hypothesis that a naïve Bayes classifier suffices to obtain good 
separation of brain tissue and CSF. 
The naïve Bayes classifier was applied to patients having repeated CT acquisitions resulting 
in successful segmentation to the degree of intensity variability seen in our sample, and 
showing low variability in volumes estimated on repeated acquisitions, see Table 3. 
Application of brain volume segmentation on a big sample of elderly individuals 
Further, brain volume estimation was applied on a larger dataset of 248 individuals aged 85 
who had undergone CT examinations, see Table 4. Volumes of total ICV for the whole 
cohort resulted in gender differences, men having larger volumes compared to women (One-
tail Student's t-test, p = 0). Similarly, men had larger total brain volume (One-tail Student's t-
test, p = 0) and CSF volumes when compared to women (One-tail Student's t-test, p ~ 0). 
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Table 3 Regional volumes from 10 patients scanned twice the same day. 
 Brain Tissue CSF 
Volume 
[milliliters] 
Baseline Replicate Baseline Replicate 
 593 595 666 669 
 1048 1051 134 124 
 1116 1093 96 118 
 997 967 143 164 
 1211 1198 307 321 
 1149 1120 236 263 
 1235 1201 250 276 
 873 874 137 133 
 1061 1060 68 64 
 834 819 370 399 
Mean 
[SD] 
1012 
[197] 
998 
[189] 
241 
[178] 
253 
[180] 
Brain tissue and CSF volumes obtained by extending the proposed algorithm for automated CT segmentation on 
10 patients with a replicate the same day. Brain Tissue: GM + WM, GM: gray matter, WM: white matter, CSF: 
cerebrospinal fluid, CT: computed tomography, SD: standard deviation. 
 
Table 4 Estimated brain volumes from 248 individuals. 
[milliliters] Male Female Non-demented Demented 
TICV 1472 ± 114 1277 ± 99 1359 ± 138 1337 ± 177 
Brain 1218 ± 114 1077 ± 111 1139 ± 129 1093 ± 149 
CSF 255 ± 76 200 ± 78 220 ± 83 244 ± 66 
Data is reported as mean ± SD. Two hundred forty-eight 85-year-olds born between 1923-1924 part of a 
population-based study. TICV: Total intracranial volume, CSF: cerebrospinal fluid, SD: standard deviation. 
Effect of white-matter changes on segmented volumes 
After stratification of the scans into those having white-matter changes (WMCs) based on 
visual assessment by a trained neuroradiologist, there was an association of larger CSF 
volumes when WMCs were present compared to absence of them (One-tail Student's t-test, p 
= 0.002). However, the association of larger CSF volumes with the presence of WMCs was 
only significant in the female group (One-tail Student's t-test, p = 0.0002). Also in non-
demented women, the presence of WMCs was associated with larger CSF volumes (One-tail 
Student's t-test, p = 0.0004). The presence of WMCs did not significantly change the 
observation that demented women had smaller CSF volumes compared to non-demented 
(One-tail Student's t-test, p = 0.0008). 
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ICV comparison for two population-based cohorts 
A previous study reported ICV averages for a population-based cohort of 85-year-olds born 
1901-1902 [186]. The population cohort in these preliminary studies consisted of 85-year-
olds born 20 years apart compared to the publication by Skoog; see Table 5 for a comparison 
of average ICV for these two cohorts. 
In both cohorts, men had larger ICV compared to women, moreover demented people had an 
associated smaller ICV. Worthy of note, there was a more balanced number of demented and 
non-demented participants recruited in the publication by Skoog compared to the cohort used 
for these studies. 
 
Table 5 Comparison of two population-based cohorts born 20 years apart. 
TICV [milliliters] Cohort I Cohort II 
Non-demented (135) (224) 
 
1268 ± 160 1359 ± 138 
Demented (104) (24) 
 1201 ± 165 1337 ± 177 
Male (74) (101) 
 1349 ± 164 1472 ± 114 
Female (165) (147) 
 1189 ± 140 1277 ± 99 
Data is reported as mean ± SD; number of subjects is stated in parentheses. Cohort I corresponds to two 
hundred thirty-nine 85-year-olds born between 1901-1902 (Skoog et al., NEJM 328 (1993) 153-158). Cohort 
II corresponds to two hundred forty-eight 85-year-olds born between 1923-1924. TICV = total intracranial 
volume, SD = standard deviation 
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7  DISCUSSION 
Development and longitudinal validation of a structural index from statistical models of 
AD-like patterns of atrophy (Studies I-III)  
Neuroimaging studies for individual classification of AD patients from cognitively normal 
aging and prediction of conversion of MCI patients show considerable variability. This could 
reflect methodological differences in scanning parameters, design of statistical analysis or 
diagnostic criteria. Besides, there are also differences due to the sample, younger versus older 
populations or small versus big number of individuals. Finally, differences due to genetic, 
ethnical, social and environmental factors should not be ignored. 
Normalization of volumes by ICV and optimal combination of brain measures in AD 
It has been confirmed that patterns of atrophy as markers of disease were not only more 
sensitive than single regions of interest analysis but also more specific [142]. This study also 
demonstrated that registration, a preprocessing step, can influence the classification results. 
Moreover the use of gray matter (GM), white matter and CSF maps could lead to worse 
results compared to only using GM maps. 
Given that GM appeared to be the most prominent marker of AD pathology, in study I we 
determined the optimal normalization approaches and the optimal combination of measures 
of GM atrophy that better classify AD patients and better predict MCI conversion. The 
hypothesis was that regional volumetric measures should be normalized by total ICV, and a 
combination of normalized volumes and un-normalized cortical thickness measures would 
generate the most accurate predictions. Besides division, it is possible to regress out ICV and 
remove its effect altogether, however removing all variance associated with ICV from 
regional brain volumes may also remove volume differences linked to protective or 
compensatory mechanisms such as brain reserve, since having a larger brain can have a 
protective effect against dementia onset. 
For individual classification of AD patients from normal aging individuals, study I confirmed 
that normalized cortical thickness measures yield significantly lower prediction accuracies 
compared to raw cortical thickness measures [187]. And that volume normalization by 
division by ICV should be applied even when multivariate modeling is performed since this 
may facilitate interpretation and comparison between individuals [188]. For optimal 
discrimination, the combination of cortical and subcortical measures resulted in the best 
prediction accuracy. Thus it is not patterns of cortical reduction alone but optimally combined 
with patterns of subcortical atrophy that could become a reliable marker of AD pathology. 
The optimal combination of cortical and subcortical measures was done in a hierarchical 
fashion because this approach treats each type of measure independently. In cases of 
overlapping information, OPLS considers only variation not already provided by other 
measures [189]. 
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The approach taken in study I had several limitations. The ADNI data originated from a 
multi-center study where different scanners were used, however, a sequence customized to 
ensure compatibility across scanners was used. The FreeSurfer pipeline was used to obtain 
regional measures deeming our results not applicable to studies using GM maps or other 
pipelines. The ADNI sample may not be representative of the general population, however 
several studies make use of it facilitating comparison with other groups. 
Linear and non-linear classifiers for individual classification in AD 
Previous studies demonstrated accurate individual classification by training linear classifiers 
and a recent review showed that SVM became the most popular and validated statistical 
learning technique in AD research studies [132], [135], [142], [144], [145], [152]. As an 
alternative to SVM we have proposed the use of OPLS for studies of individual classification, 
however, other techniques do exist. Therefore, in study II we aimed to assess the 
classification ability of different statistical learning techniques for individual classification of 
AD and prediction of MCI conversion at one-year follow-up. We also studied the effect of 
age, education and APOE genotype (ε4 carriers vs non-carriers) to determine the optimal 
learning technique. 
In particular, we investigated whether classification performance could be improved by 
considering three non-linear classifiers: gaussian SVM, Trees and ANN. We speculated that 
adding age and education to our models, or adding APOE genotype information could 
enhance prediction accuracy. Finally, we hypothesized that considering all variables 
simultaneously would allow the model to capture widespread AD-like patterns of atrophy as 
opposed to selecting the top most informative ones. 
The statistical learning techniques considered in study II were equally accurate in their 
discrimination ability for AD classification; however, they differ in their ability to predict 
conversion from MCI to AD. Worse performance in prediction of conversion was observed 
in Trees, probably due to the intrinsic variable selection performed as part of the learning. 
This provided support to our idea that keeping all variables rather than a selected set would 
increase discrimination ability. Also, limitations in the data, such as clinical diagnosis, 
inclusion/exclusion criteria, segmentation algorithm employed, should have a greater effect 
on individual classification rather than the classifier chosen to build the statistical model. This 
has also been concluded later when a review of the literature was carried out: the quality of 
the data rather than the statistical learning technique chosen has a higher impact on individual 
classification in AD [152]. These results support our view that extracting relevant information 
from structural neuroimaging demands statistical learning techniques capable of modeling 
patterns of atrophy. Moreover, the regions selected as most relevant overlapped among the 
considered classifiers. We found that hippocampus remained the single most relevant 
measure strongly associated with dementia diagnosis [190]. Contrary to our initial hypothesis, 
the addition of age, education level or APOE phenotype did not significantly improve 
classification accuracy. A potential explanation for this finding may be that for a linear 
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classifier such as OPLS, addition of other variables besides the ones derived from sMRI had a 
marginal effect since patterns of brain atrophy were stronger predictors of AD in and of itself. 
Assessment of an MRI-based index for individual classification in AD 
The study of the temporal evolution of patterns of atrophy in longitudinal studies is a 
necessary step in the validation of a potentially relevant clinical biomarker; for instance, 
convergence to a definite prediction over time should be demonstrated. However, such 
analysis requires the simultaneous study of all measures since each individual region follows 
its own trajectory over time. To ease the complexity burden and simplify interpretation, 
structural indices describing disease patterns were constructed [138], [140], [147], [191], 
[192]. 
In study III we extended the analysis of discriminative patterns of atrophy from studies I and 
II by deriving an MRI-based index reflecting AD-like patterns of atrophy. Our results 
revealed that diagnostic groups could be differentiated based on their average scores. 
Although all groups showed increased atrophy over time, the AD group displayed an 
accelerated rate thus giving support to the idea that AD unlike normal aging is characterized 
by an accelerated loss of brain tissue mainly in medial temporal lobe structures [129]. The 
increase in sensitivity at the expense of reduced specificity was previously reported and 
thought to be due to a convergence of phenotypic expression of AD pathology, and an 
accumulation of AD-like atrophy in cognitively normal individuals over time [41], [43], [44]. 
Another reason may be that brain regions vulnerable to the normal aging process are already 
evident after only one-year and overlap with those vulnerable to AD, such as the default 
mode network [128], [150]. We reported a group of oldest old individuals with normal 
cognition and high scores typical of AD patients. No further conclusions can be derived about 
this group since knowledge about AD pathology has been derived from populations of elderly 
people not representative of the oldest old [45], [46], [58]. MCI patients carrying the APOE 
ε4 allele displayed greater atrophy and more cognitive impairment supporting the idea they 
are not only at a higher risk of developing dementia, but also expressed a phenotype more 
typical of AD patients [53]–[56]. 
An important limitation of study III was the very short follow-up (one year), and that no 
definite diagnosis of AD was obtained. Also, there was no additional biomarker information 
to support diagnosis and we did not consider alternative summary scores for longitudinal 
cognitive performance besides averaging [193], [194]. 
These three studies demonstrated that statistical learning provides a promising way for 
individual patient classification in a fully automated and unbiased fashion. Open questions 
not covered in this thesis were the integration of additional clinical, biochemical and genetic 
information, as well as how early can AD be detected? 
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Intracranial volume estimation from computed tomography scans (Study IV) 
Despite the fact that for research purposes MRI is the most popular neuroimaging modality, 
in primary care CT remains widely used for dementia investigations [95]. Therefore, we have 
aimed to tackle the problem of automated ICV estimation from CT head scans demanding 
high accuracy, reliability, reproducibility and robustness. 
We developed an automated segmentation algorithm by fitting the parameters of the joint 
intensity distribution of brain tissue and CSF applying the EM algorithm [172]. Our proposed 
automated segmentation algorithm achieved successful segmentation to the degree of 
intensity variability seen in our sample, and in good agreement with manual delineation set as 
gold standard. This confirmed our initial hypothesis that modeling of the intensity 
information would be enough for adequate segmentation and was probably due to the high 
contrast between brain parenchyma and skull.  There was also high correlation with volumes 
estimated from MRI, suggesting that estimation of ICV from accurate segmentation of CT 
head scans is feasible. The low variability in repeated acquisitions supports our idea that 
automated and unbiased measures of brain volumes should be preferred. 
Limitations of our approach are that only a limited number of patients were considered, 
however patients with repeated acquisitions on CT and MRI modalities are highly 
uncommon. Also, beam-hardening and partial volume artifacts were not corrected for, which 
may reduce the size of the intracranial cavity. Finally, no spatial information was collected to 
refine the segmentation, a popular approach among MRI-based algorithms. 
Preliminary studies: estimation of brain and CSF volumes from brain parenchyma 
Although the impact of brain pathology on the risk of dementia is modified by ICV in 
demented old patients [123], [195], ICV does not correlate well with cognitive function 
[183]. Estimation of brain and CSF volumes has shown better association with cognition and 
thus would be of clinical relevance.  
In these preliminary studies, we aimed at extending the segmentation algorithm proposed in 
study IV. Our results confirmed accuracy of our segmentation algorithm on estimates of brain 
and CSF volumes by application of the Naïve Bayes classifier. Although, there was a larger 
variance in these volumes compared to the variance found in estimating ICV. However, there 
was good agreement between repeated measures on the same individual. Additionally, a 
larger dataset of demented and non-demented patients was processed by our proposed 
algorithm and estimates of ICV, CSF and brain volumes were compared to a similar cohort of 
patients born 20 years before. Comparing the volumes between the two cohorts born 20 years 
apart, we could observe similar trends in the data: ICVmen > ICVwomen and ICVnon-demented > 
ICVdemented. 
Limitations of our approach include a lack of a gold standard to assess the accuracy of our 
approach, but this would require very time-consuming manual tracing that would be 
necessary as final validation. Also, we observed differences in the estimated CSF volumes if 
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WMCs were present, suggestive of a potential partial volume artifact that should be 
accounted for. Finally, spatial information should be collected in order to refine the 
segmentation, and although that should help to better delineate the CSF-brain tissue 
boundary, it most probably would increase the computational complexity. Besides, the 
clinical utility of such refinement needs to be evaluated to determine its added value. 
As proof of concept we have extend our segmentation algorithm to estimate brain and CSF 
volumes, however, the presence of WMCs could potentially have biased our results and we 
speculate that spatial information may be necessary to achieve more detailed refinement. 
Future work should focus on demonstrating the association of brain volume estimates and 
cognitive function, as well as longitudinal evaluation to demonstrate if this technique is 
sensible enough and adequate to track changes in time. 
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8 CONCLUSIONS AND FUTURE PERSPECTIVES 
Brain atrophy changes are part of normal aging and perhaps AD is the result of accumulated 
negative assaults resulting in an accelerated and ordered pathological spreading leading to 
impaired cognition. However, even if the disease maintains its predictive progression, there is 
enough individual variability associated with the maintenance of cognitive function indicative 
of a reduction in the effects of AD pathology that such factors deserve further study [196]–
[198].  
The main contributions from this thesis are: 
 Determination of an optimal combination of brain measures to model patterns of 
atrophy typical of AD. 
 Simplification of the interpration of complex statistical models by deriving an MRI-
based index to estimate the individual’s risk(s) of developing AD. 
 Characterization and longitudinal validation of a structural index that reflects patterns 
of AD-like brain atrophy. 
 Development and validation of a segmentation algorithm for accurate estimation of 
ICV. 
 Development of a segmentation algorithm of the brain parenchyma by modeling the 
joint intensity distribution of brain and CSF tissue. 
The studies contained in this thesis applied computerized tools to the problem of AD 
diagnosis, achieving accurate individual prediction of disease status and conversion from 
prodromal stages. Key in the identification and validation of patterns of atrophy is the 
observation that changes in cognitive function are caused by structural and functional 
changes in the brain. However, several challenges remained to facilitate the integration of 
such tools in clinical practice [199]–[202].  At the same time, computerized tools that are 
unbiased and automated should be preferred and substitute time-consuming and error-prone 
user-dependent methods. Besides, the knowledge and understanding brought about 
neurodegenerative pathology is only a part of the big picture, and needs to be complemented 
by studies that look to elucidate the neuronal/histological substrates of cognitive reserve to 
shed light on the biological mechanisms behind mental resilience [203]; so that protective and 
detrimental factors can be linked to specific etiology. 
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